Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant - Olema Pharmaceuticals (NASDAQ:OLMA)

Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,San Francisco ,California ,Spain ,Madrid ,Boston ,Geoffrey Mogilner ,Nancy Lin ,Seanp Bohen ,Ignacio Guerrero Ros ,Olema Pharmaceuticals Inc ,Division Of Breast Oncology ,Company Investor Webcast ,Linkedin ,Exchange Commission ,Securities Exchange ,Twitter ,Susanf Smith Center ,European Society For Medical Oncology ,Nasdaq ,European Society ,Medical Oncology ,Chief Executive Officer ,Recommended Phase ,Investor Webcast ,Associate Chief ,Breast Oncology ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Vice President ,Investor Relations ,